- Home
- CGAU vs DNLI Comparison
CGAU vs DNLI Comparison
Compare CGAU & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CGAU | DNLI |
|---|---|---|
| Founded | 2002 | 2013 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.7B |
| IPO Year | 2021 | 2017 |
Fundamental Metrics
Financial Performance| Metric | CGAU | DNLI |
|---|---|---|
| Price | $15.81 | $22.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 14 |
| Target Price | $16.67 | ★ $34.33 |
| AVG Volume (30 Days) | 1.4M | ★ 2.0M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.16% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $25.17 | N/A |
| Revenue Next Year | $13.62 | $408.85 |
| P/E Ratio | $11.74 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.71 | $12.58 |
| 52 Week High | $21.17 | $27.30 |
Technical Indicators
Market Signals| Indicator | CGAU | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 45.51 | 44.38 |
| Support Level | $15.12 | $18.27 |
| Resistance Level | $19.95 | $23.27 |
| Average True Range (ATR) | 0.62 | 1.39 |
| MACD | 0.02 | -0.45 |
| Stochastic Oscillator | 33.00 | 17.39 |
Price Performance
Historical ComparisonAbout CGAU Centerra Gold Inc.
Centerra Gold Inc is principally focused on operating, developing, exploring and acquiring gold and copper properties in North America, Turkey, and other markets world-wide. The company reportable operating segments are Oksut; Mount Milligan; and Molybdenum. It derives maximum revenue from Mount Milligan segment. Geographically, it operates in Turkey, United States, and Canada.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.